Acoramidis (formerly AG10) is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin, or TTR, thereby halting at its outset the series of molecular events that give rise to TTR amyloidosis, or ATTR.
For research use only. We do not sell to patients.
Name | Acoramidis (AG-10 ) |
---|---|
Iupac Chemical Name | 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid |
Synonyms | Acoramidis ; AG-10 ; AG10 ; AG 10 |
Molecular Formula | C15H17FN2O3 |
Molecular Weight | 292.31 |
Smile | Cc1n[nH]c(C)c1CCCOc2cc(ccc2F)C(=O)O |
InChiKey | WBFUHHBPNXWNCC-UHFFFAOYSA-N |
InChi | InChI=1S/C15H17FN2O3/c1-9-12(10(2)18-17-9)4-3-7-21-14-8-11(15(19)20)5-6-13(14)16/h5-6,8H,3-4,7H2,1-2H3,(H,17,18)(H,19,20) |
CAS Number | 1446711-81-4 |
Related CAS | 1446711-81-4 |
Packaging | Price | Availability | Purity | Shipping Time |
---|---|---|---|---|
Bulk | Enquiry | Enquiry | Enquiry |
Formulation | Off-white solid |
---|---|
Purity | ≧98.0% |
Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
Solubility | Soluble in DMSO |
Handling | |
Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
HS Code |
Targets | |
---|---|
Mechanism | |
Cell study | |
Animal study | |
Clinical study |
1: Judge DP, Falk RH, Maurer MS, Shah SJ, Witteles RM, Grogan M, Selby VN, Jacoby D, Hanna M, Nativi-Nicolau J, Patel J, Rao S, Sinha U, Turtle CW, Fox JC, Heitner SB. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2019 Mar 12. pii: S0735-1097(19)33920-8. doi: 10.1016/j.jacc.2019.03.012. [Epub ahead of print] PubMed PMID: 30885685.
2: Miller M, Pal A, Albusairi W, Joo H, Pappas B, Haque Tuhin MT, Liang D, Jampala R, Liu F, Khan J, Faaij M, Park M, Chan W, Graef I, Zamboni R, Kumar N, Fox J, Sinha U, Alhamadsheh M. Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis. J Med Chem. 2018 Sep 13;61(17):7862-7876. doi: 10.1021/acs.jmedchem.8b00817. Epub 2018 Aug 22. PubMed PMID: 30133284; PubMed Central PMCID: PMC6276790.
3: Petty JT, Sergev OO, Ganguly M, Rankine IJ, Chevrier DM, Zhang P. A Segregated, Partially Oxidized, and Compact Ag10 Cluster within an Encapsulating DNA Host. J Am Chem Soc. 2016 Mar 16;138(10):3469-77. doi: 10.1021/jacs.5b13124. Epub 2016 Mar 7. PubMed PMID: 26924556; PubMed Central PMCID: PMC6118400.
4: Penchala SC, Connelly S, Wang Y, Park MS, Zhao L, Baranczak A, Rappley I, Vogel H, Liedtke M, Witteles RM, Powers ET, Reixach N, Chan WK, Wilson IA, Kelly JW, Graef IA, Alhamadsheh MM. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9992-7. doi: 10.1073/pnas.1300761110. Epub 2013 May 28. PubMed PMID: 23716704; PubMed Central PMCID: PMC3683741.
5: Avlonitis N, Chalmers S, McDougall C, Stanton-Humphreys MN, Brown CT, McCarron JG, Conway SJ. Caged AG10: new tools for spatially predefined mitochondrial uncoupling. Mol Biosyst. 2009 May;5(5):450-7. doi: 10.1039/b820415m. Epub 2009 Mar 31. PubMed PMID: 19381360.
6: Soltoff SP. Evidence that tyrphostins AG10 and AG18 are mitochondrial uncouplers that alter phosphorylation-dependent cell signaling. J Biol Chem. 2004 Mar 19;279(12):10910-8. Epub 2003 Dec 19. PubMed PMID: 14688271.